Display options
Cite
Bae S, Wong HL, Tie J, et al. Impact of Diabetes Status and Medication on Presentation, Treatment, and Outcome of Stage II Colon Cancer Patients. J Cancer Epidemiol. 2015;2015:189132doi: 10.1155/2015/189132.
Bae, S., Wong, H. L., Tie, J., Desai, J., Field, K., Kosmider, S., Fourlanos, S., Jones, I., Skinner, I., & Gibbs, P. (2015). Impact of Diabetes Status and Medication on Presentation, Treatment, and Outcome of Stage II Colon Cancer Patients. Journal of cancer epidemiology, 2015189132. https://doi.org/10.1155/2015/189132
Bae, Susie, et al. "Impact of Diabetes Status and Medication on Presentation, Treatment, and Outcome of Stage II Colon Cancer Patients." Journal of cancer epidemiology vol. 2015 (2015): 189132. doi: https://doi.org/10.1155/2015/189132
Bae S, Wong HL, Tie J, Desai J, Field K, Kosmider S, Fourlanos S, Jones I, Skinner I, Gibbs P. Impact of Diabetes Status and Medication on Presentation, Treatment, and Outcome of Stage II Colon Cancer Patients. J Cancer Epidemiol. 2015;2015:189132. doi: 10.1155/2015/189132. Epub 2015 May 05. PMID: 26074965; PMCID: PMC4436511.
Copy Download .nbib Format: NLM
Share it on

J Cancer Epidemiol. 2015;2015:189132. doi: 10.1155/2015/189132. Epub 2015 May 05.

Impact of Diabetes Status and Medication on Presentation, Treatment, and Outcome of Stage II Colon Cancer Patients.

Journal of cancer epidemiology

Susie Bae, Hui-Li Wong, Jeanne Tie, Jayesh Desai, Kathryn Field, Suzanne Kosmider, Spiros Fourlanos, Ian Jones, Iain Skinner, Peter Gibbs

Affiliations

  1. Royal Melbourne Hospital, Melbourne, VIC 3050, Australia.
  2. Royal Melbourne Hospital, Melbourne, VIC 3050, Australia ; Western Hospital, Footscray, VIC 3011, Australia.
  3. Royal Melbourne Hospital, Melbourne, VIC 3050, Australia ; BioGrid Australia, Melbourne, VIC 3050, Australia.
  4. Western Hospital, Footscray, VIC 3011, Australia.
  5. Royal Melbourne Hospital, Melbourne, VIC 3050, Australia ; Western Hospital, Footscray, VIC 3011, Australia ; BioGrid Australia, Melbourne, VIC 3050, Australia.

PMID: 26074965 PMCID: PMC4436511 DOI: 10.1155/2015/189132

Abstract

Diabetes is a risk factor for colorectal cancer and several reports suggest worse cancer-specific outcomes in diabetes patients. Recent studies in multiple tumour types indicate metformin may positively impact on cancer-specific and overall survival. A population-based series of stage II colorectal cancer patients treated and followed from 2000 to 2013 were analysed for baseline characteristics, treatment, and outcomes. 1116 patients with stage II colon cancer were identified, 55.5% were male and median age was 70.9 years (range 20.5-101.2). The diabetes patients (21.6%, n = 241) were older than nondiabetes patients (median 74.0 versus 69.6, p = 0.0001). There was no impact of diabetes on cancer presentation or pathology. Diabetes patients were less likely to receive adjuvant treatment (13.7 versus 24.8%, p = 0.002) but were equally likely to complete treatment (69.7 versus 67.7%, p = 1.00). Diabetes did not significantly impact cancer recurrence (HR = 1.07, 95% CI 0.71-1.63) or overall survival (HR = 1.23, 95% CI 0.88-1.72), adjusted for age. Diabetes medication did not impact cancer recurrence or survival. Cancer presentation and outcomes in diabetes patients are comparable to those of nondiabetes patients in those with stage II colon cancer. The effect of metformin merits further evaluation in patients with colon cancer.

References

  1. J Clin Oncol. 2009 Jul 10;27(20):3297-302 - PubMed
  2. Cancer Epidemiol Biomarkers Prev. 2013 Aug;22(8):1364-73 - PubMed
  3. Clin Cancer Res. 2012 May 15;18(10):2905-12 - PubMed
  4. Diabetologia. 2012 Aug;55(8):2163-72 - PubMed
  5. Int J Cancer. 2012 Aug 1;131(3):752-9 - PubMed
  6. J Oncol Pract. 2008 May;4(3):108-13 - PubMed
  7. J Clin Oncol. 2012 Jan 1;30(1):53-9 - PubMed
  8. Dig Dis Sci. 2012 Jun;57(6):1576-85 - PubMed
  9. Br J Cancer. 2012 Apr 10;106(8):1374-8 - PubMed
  10. J Clin Oncol. 2013 Sep 1;31(25):3069-75 - PubMed
  11. Diabetes Care. 2013 Aug;36 Suppl 2:S240-4 - PubMed
  12. J Clin Oncol. 2003 Feb 1;21(3):433-40 - PubMed
  13. J Clin Oncol. 2012 Jul 20;30(21):2698-700 - PubMed

Publication Types